Program
belacabnagene franleucel
Its studies are mostly in Scleroderma, Systemic · Lupus Nephritis · Lymphoma, Mantle-Cell, led by Nkarta.
Furthest: phase 2, since Jul 10, 20243 company-led studies, 3 open or runningNext primary completion: Apr 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Nkarta | 33 open or running | phase 2since Jul 10, 2024 | Aug 20, 2021 | Apr 2027phase 2 · NCT06557265 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 20, 2021First study: phase 1 study in Lymphoma, Non-HodgkinFirst studyNCT05020678 · 150 enrolled · United States, Australia
- Jul 10, 2024Phase 2 study in Lupus NephritisNCT06557265 · 120 planned · United States, Australia, Puerto Rico
- Dec 4, 2024Phase 2 study in Scleroderma, SystemicNCT06733935 · 240 planned · United States
Ahead
- Apr 2027Primary completion: phase 2 study in Lupus NephritisNCT06557265
- Oct 2028Primary completion: phase 2 study in Scleroderma, SystemicNCT06733935
TargetBeta
“A preparation of off-the-shelf (OTS), allogeneic and ex vivo expanded natural killer cells (NKs) that are engineered to express membrane-bound IL-15 (mbIL15) and a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 that is coupled to the ”NCIt, by rule
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06733935Scleroderma, Systemic · United States | 2 | Recruiting | Oct 2028 | 240 |
| NCT06557265Lupus Nephritis · United States, Australia, Puerto Rico | 2 | Recruiting | Apr 2027 | 120 |
| NCT05020678Lymphoma, Non-Hodgkin · United States, Australia | 1 | Active, not recruiting | Mar 31, 2025 | 150 |
How it is read
Names in the registry
- “NKX019”, 3 entries
Conditions, from the studies’ own filings
- Scleroderma, Systemic, 1 study
- Lupus Nephritis, 1 study
- Lymphoma, Mantle-Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.